PwPepwise

Substance P

Pain & Nerves

Neurokinin / undecapeptide

Substance P is a naturally occurring neuropeptide — a small protein-like molecule — produced throughout the nervous system.

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
NK1 antagonist therapeutics targeting substance P signaling85 mg—OralTaken by mouth.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Substance P is a naturally occurring neuropeptide — a small protein-like molecule — produced throughout the nervous system, where it plays a central role in transmitting pain signals, regulating mood, and controlling inflammation. It acts primarily by binding to a receptor called NK1 (neurokinin-1), triggering effects ranging from vasodilation and immune activation to the amplification of moderate-to-intense pain signals10. Research in both animals and humans has established that substance P is particularly important for the experience of moderate-to-severe pain and the development of heightened pain sensitivity, while milder pain sensations appear to travel through separate pathways10.

Rather than being administered therapeutically, substance P is most relevant today as a biological target — meaning that blocking its receptor with NK1 antagonist drugs has produced clinically validated benefits. NK1 receptor antagonists have demonstrated efficacy in preventing chemotherapy-induced nausea and vomiting9 and have received FDA approval for motion sickness prevention11. Early clinical evidence also suggested potential antidepressant activity through a mechanism distinct from conventional treatments1. Substance P's role in headache, chronic pain, and neuroinflammation is actively being investigated, with registered clinical trials currently underway2,3.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Substance P is an 11-amino acid neuropeptide of the tachykinin family, encoded by the preprotachykinin A (PPT-A) gene alongside neurokinin A10. It exerts its biological effects primarily through the NK1 (neurokinin-1) receptor, a G protein-coupled receptor (GPCR) belonging to the rhodopsin-type superfamily with seven transmembrane-spanning domains — a structural family first confirmed for tachykinin receptors through cDNA cloning of the closely related substance-K receptor7. NK1 receptor activation couples to Gq/11 proteins, stimulating phospholipase C-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate to generate inositol trisphosphate (IP3) and diacylglycerol (DAG)13. IP3 triggers intracellular calcium release, while DAG activates protein kinase C, initiating downstream signaling cascades that regulate neuronal excitability, inflammatory gene expression, and smooth muscle contractility9,13.

In the nociceptive system, substance P is synthesized in small-diameter primary afferent neurons — predominantly C-fibers and Aδ fibers — and transported to both peripheral terminals and central synaptic boutons in laminae I–III of the spinal cord dorsal horn15,16. Release from central terminals in response to noxious stimuli activates NK1 receptors on projection neurons in lamina I, a population whose selective ablation markedly attenuates responses to intense noxious stimuli and hyperalgesia while leaving mild nociception intact8. PPT-A knockout studies confirm that tachykinin release is specifically required for the experience of moderate-to-intense pain, with glutamate-mediated pathways remaining sufficient for mild stimuli10. This intensity-dependent gating role positions the substance P/NK1 axis as a mediator of central sensitization and wind-up phenomena rather than baseline nociception6.

In the vascular system, substance P induces endothelium-dependent relaxation by stimulating endothelial cells to release nitric oxide (NO) via endothelial nitric oxide synthase (eNOS)14,19. eNOS knockout mice demonstrate absent substance P-induced vasodilation, confirming eNOS as an obligate mediator of this response5. The vasodilatory effect is therefore contingent on intact endothelial function, with impaired endothelium shifting the response profile toward absent or attenuated relaxation19.

In the central nervous system, substance P signaling in limbic and brainstem circuits modulates emotional processing, stress responses, and emetic pathways1,9. NK1 receptors in these regions are the mechanistic basis for the antiemetic efficacy of NK1 antagonists and for the antidepressant signal observed in early clinical investigation1,11. Substance P also participates in neurogenic inflammation through peripheral NK1 receptor activation, driving plasma extravasation, mast cell degranulation, and sensitization of primary afferents — a process relevant to migraine pathogenesis currently under direct clinical investigation2,3,9.

§04Evidence & efficacy

Evidence base
262Studies
95Human
85Animal

Substance P's most clinically validated role is as a therapeutic target rather than a therapeutic agent. NK1 receptor antagonists, which block substance P signaling, reduce vomiting incidence in motion sickness — tradipitant at 170 mg reduced vomiting to 18.3% versus 44.3% for placebo in one Phase 3 trial, and to 10.4% versus 37.7% for placebo in a second Phase 3 trial11. NK1 antagonists also represent a validated drug class for chemotherapy-induced nausea and vomiting9.

In a landmark placebo-controlled clinical trial published in Science, the NK1 antagonist MK-869 demonstrated antidepressant effects in patients with moderate-to-severe major depression, operating through a mechanism distinct from monoaminergic systems1. This early finding positioned substance P antagonism as a potentially novel psychiatric therapeutic target, and this area of investigation remains active9.

Preclinical evidence consistently demonstrates that substance P mediates moderate-to-intense pain and central sensitization. PPT-A knockout mice lacking substance P showed significantly reduced responses to moderate-to-intense stimuli10, NK1 receptor knockout mice lacked wind-up amplification of nociceptive reflexes6, and selective ablation of NK1-expressing lamina I spinal neurons markedly attenuated hyperalgesia8. Whether these mechanistic findings translate to clinical analgesic benefit from NK1 antagonism is being investigated, with the evidence base actively developing9.

Substance P's capacity to trigger migraine attacks in susceptible individuals is under direct clinical investigation in registered RCTs2,3, with results anticipated to clarify its role as a headache mediator.

§05Safety

The safety profile of exogenous substance P in humans is characterized primarily through its use as a pharmacodynamic challenge agent and vascular research tool rather than as a therapeutic. Intradermal administration is expected to produce localized wheal-and-flare skin reactions, consistent with its known role in neurogenic inflammation12. Systemic administration is associated with vasodilation and potential flushing, reflecting its endothelium-dependent relaxing activity mediated through nitric oxide release14,19. These cardiovascular effects are being prospectively monitored in ongoing intravenous provocation trials2,3.

For NK1 receptor antagonists — the drug class that modulates substance P signaling — the human safety record is more established. Tradipitant at both 85 mg and 170 mg oral doses demonstrated a favorable safety profile across two Phase 3 trials with no serious adverse events reported11. MK-869, studied in a placebo-controlled antidepressant trial, did not report significant safety signals in the available record1.

In animal models, NK1 receptor knockout mice were reported to be healthy and fertile, suggesting that disruption of substance P signaling does not produce gross developmental or systemic toxicity6. PPT-A knockout mice lacking substance P also showed normal baseline health and sensory function10.

§06History

Substance P was first identified in 1931 by von Euler and Gaddum as a biologically active peptide extract from equine brain and intestine capable of causing smooth muscle contraction and vasodilation — its name derived from the powder ('P') form of the original preparation. Its 11-amino acid sequence was definitively elucidated in 1970 by Chang, Leeman, and Niall. Seminal immunohistochemical work in the mid-1970s by Hökfelt and colleagues established its localization in small-diameter primary sensory neurons and spinal cord dorsal horn laminae, providing the anatomical foundation for substance P as a pain neurotransmitter15,16.

The 1980s brought key mechanistic advances: substance P was identified as an agonist activating phosphatidylinositol signaling cascades13, and its endothelium-dependent vasodilatory mechanism through EDRF/nitric oxide was characterized14,19. The cloning of the substance-K receptor in 1987 confirmed tachykinin receptors as members of the GPCR rhodopsin superfamily7, accelerating drug discovery efforts.

The 1990s marked a pivotal translational era. Genetic knockout studies definitively established substance P's role in moderate-to-intense pain and central sensitization6,10, and spinal NK1 neuron ablation confirmed the lamina I pathway's role in pathological pain8. A landmark 1998 Science publication reported antidepressant effects of the NK1 antagonist MK-869 in a placebo-controlled trial1, generating significant pharmaceutical interest. The subsequent decade saw NK1 antagonists validated clinically for chemotherapy-induced nausea and vomiting9. Most recently, tradipitant received FDA approval for motion sickness in 202511, and new clinical trials investigating substance P's direct role in migraine provocation are actively recruiting2,3.

§07References